Business Wire

GIST-IMPACT

20.6.2024 08:01:35 CEST | Business Wire | Press release

Share
GIST Impact, a leading impact data and analytics provider, receives investment from UBS Next

Today GIST Impact, the leading provider of impact data and analytics, announced an investment from UBS Next, the leading universal Swiss bank’s venture and innovation unit.

GIST Impact delivers actionable impact intelligence to companies and investors, helping them easily measure their environmental and social impacts. The firm’s data and software are founded on a science-based, location-specific and standards-aligned approach, drawing on over 16 years of experience measuring and valuing impact. Its clients include some of the world’s largest banks, sovereign wealth funds, and technology firms.

The provision of better impact data is critical in developing greater transparency for investors to help them manage their portfolios. New regulations and standards have also set a higher bar for measuring impact across value chains - whether through assessing impact materiality as part of the Corporate Sustainability Reporting Directive (CSRD) or evaluating natural capital impact as part of the Taskforce on Nature-related Financial Disclosures (TNFD).

The investment from UBS Next will support the further expansion of GIST Impact’s product integrations with partners and development of proprietary impact data and software solutions, including preparations for CSRD and TNFD requirements where clients require most support.

Andre Hoffmann, Co-Founder of GIST Impact, said, “This partnership with UBS marks a pivotal moment for GIST Impact as we set new standards for how companies and investors can integrate environmental and social considerations into their core business strategies. Our collaboration is more than an investment; it's a shared commitment to foster a more sustainable future where financial success is inextricably linked to positive impact on the planet and society. We are thrilled to join forces with UBS to drive this change forward, ensuring that our clients are not just prepared for the future but are actively shaping it."

“We believe that actionable impact intelligence and data will help investors manage their portfolios in a targeted manner and match opportunities and environmental and social impact. This is a pre-requisite to create long-term sustainable outcomes,” said Sergio Ermotti, Group CEO of UBS.

“We’re proud to partner with UBS to accelerate this next stage in our growth. Our world-leading impact data and intelligence algorithms empower investors to manage their portfolios towards better social and environmental outcomes and impacts,” said Pavan Sukhdev, Co-Founder and CEO of GIST Impact. “Furthermore, our impact valuation platforms help companies evaluate their impacts, dependencies, risks and opportunities, helping create long-term sustainable value.”

About GIST Impact

GIST Impact is a market-leading impact data and analytics provider, measuring, quantifying and valuing corporate impacts on society and the environment for over 16 years. With a team of 120+ data scientists, engineers, ecologists and economists, GIST Impact delivers location-specific impact data covering 14,500+ companies. Since 2021, the firm has automated its systems to provide investment portfolio impacts, and its clients include investors representing over $8 trillion in assets under management as well as leading global corporations. GIST Impact also partners with some of the largest consulting firms, business networks, and fintech platforms to enable impact measurement and reporting across global markets.

https://gistimpact.com/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240619424763/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 15:07:00 CEST | Press release

Initial planning calls for Data Sciences Division to focus efforts in cyber secure infrastructure with dedication in fintech and patented Information Data Exchange® (IDE®) Management will harness its API Media acquisition, robust patent portfolio, ADIO® Inaudible Tones, WiSA® and Dolby® partnerships to establish worldwide acoustic industry standards in high-definition wireless transmission, spatial-audio control and interoperability Plan includes API media’s stand-alone and renewed execution of WiSA semiconductor and software modules strategy with an R&D effort targeted to new robotic and drone applications Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™,

Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 14:50:00 CEST | Press release

First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs)at the 2026 EADV SymposiumThe vast majority of patients achieving EASI50 at Week 8 and continuing double-blind, as needed treatment with Opzelura® (ruxolitinib) cream through Week 24 demonstrated disease control, with 84.3% achieving EASI75 (a ≥75% improvement in the Eczema Area and Severity Index score from baseline) and 70.6% achieving IGA-TS (Investigator’s Global Assessment Treatment Success)Data support Type-II variation application submitted for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU), feedback expected in 1H 2026 Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with mode

Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release

Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L

2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release

“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release

Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye